Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 3 matches for

READ-OUT celebrates a milestone as its 15th clinical site accepts participants for the Blood Biomarker Challenge study

DPUK's READ-OUT study, part of the Blood Biomarker Challenge, has reached a major milestone with the commissioning of its 15th clinical site to the study. It now has half of its planned 30 sites operational, recruiting participants to the study.

We are taking bookings for our next DATATHON!

DPUK's next Datathon will be running from June 26-30 with a theme of cognitive testing.

New drug can slow Alzheimers - DPUK's reaction

In a groundbreaking study, Eli Lilly Pharmaceutical has released Donanemab, a new drug that has shown promising results in slowing down cognitive decline in patients with early Alzheimer's disease.